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Background: In this meta-analysis we aimed to determine the effectiveness and safety of hyperthermic
intraperitoneal chemotherapy (HIPC) for patients with advanced gastric cancer who underwent gastrectomy.
Methods: In accordance with standard meta-analysis procedures, our study included patients who underwent
resection for advanced gastric cancer and were randomly allocated to receive either hyperthermic intraperitoneal
chemotherapy or control. We searched PubMed (up to November 2011), EMBASE (up to November 2011), Cochrane
Database of Systematic Reviews (CDSR), and Cochrane Central Register of Controlled Trials (CCTR) (up to November
2011). Both published and unpublished trials were included in the analysis, and no search restrictions were
imposed. There was no language restriction. The results were analyzed using RevMan 5.1 software, which was
provided by Cochrane Collaboration.
Results: There were ten randomized controlled trials included in the analysis. A total of 1062 patients with gastric
cancer in these studies were divided into the HIPC group (n = 518) and control group (n = 544). A significant
improvement in survival was observed in the HIPC groups compared to the control group in the mitomycin
C (MMC) subgroup (RR = 0.75, 95%CI 0.65-0.86; P < 0.00001) and the 5-FU group (RR = 0.69, 95%CI 0.52-0.90;
P < 0.00001); the total RR was 0.73 (95%CI 0.64-0.83; P < 0.00001). Our findings indicated that HIPC potentially
exhibited a lower peritoneal recurrence rate in the HIPC group compared to the control group (RR = 0.45, 95%CI
0.28-0.72; P = 0.001).
Conclusions: Our meta-analysis demonstrated that HIPC may improve the overall survival rate for patients who
receive resection for advance gastric cancer potentially, and help to prevent peritoneal local recurrence among
patients with serosal invasion in gastric cancer.
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Although significant advances have been achieved in re-
cent years in experimental research, diagnosis, and treat-
ment of cancer, gastric cancer (GC) remains the second
most frequent cause of cancer death after lung cancer
worldwide, and exhibits a poor prognosis [1,2]. Surgical
resection plus extended lymph node dissection comprises
the primary method of curative intent for localized gas-
tric cancer, however, the 5-year survival rate remains un-
satisfactory [3,4]. Peritoneal dissemination is one of the
principal reasons for the recurrence and metastasis of
gastric cancer in the peritoneal cavity, and it has been
reported to be complicated and difficult to treat in recent
years [5]. The peritoneal seeding of gastric cancer (GC)
exhibits a high risk for patients who receive surgery
alone, and systemic chemotherapy exhibits no significant
effect [6]; the origins may be the free tumor cells from
the primary gastric cancer that remain following surgery,
or micrometastases in the peritoneal cavity [7].
In spite of the use of both systemic chemotherapy and
radiation therapy, the survival rate of patients with
advanced gastric cancer remains unsatisfactory. Adjuvant
intraperitoneal chemotherapy (IPC) is recognized as an
effective method to control peritoneal dissemination in
GC patients who have undergone resection of the pri-
mary cancer [8,9]. Intraperitoneal chemotherapy is used
to achieve longer survival by wiping out the mircometas-
tases in the abdominal cavity and free tumor cells left
after surgery that could not be cleaned up by intravenous
chemotherapy. A number of studies have investigated
whether intraperitoneal chemotherapy exhibits an effect
on patients with advanced gastric cancer, such as Xu DZ
et al. [10] and Yan TD et al. [8], and all reports reached a
positive conclusion regarding improved survival rate. Re-
cently, hyperthermia has been developed as an anticancer
therapy, and has been demonstrated to exhibit a direct
cytotoxic effect on tumor cells in the peritoneal cavity in
conjunction with some anticancer chemotherapeutic
agents [11]. Since Spratt et al. [12] reported the use of
hyperthermic intraperitoneal chemotherapy for the treat-
ment of peudomyxoma peritonei, several positive reports
regarding hyperthermic intraperitoneal treatment for
gastric cancer have been published, but the results were
not unified. The purpose of our meta-analysis was
to evaluate the effectiveness, safety, and preventive
effects of hyperthermic intraperitoneal chemotherapy for
patients with advance gastric cancer who received radical




An electronic search was applied to PubMed (up to
November 2011), EMBASE (up to November 2011),Cochrane Database of Systematic Reviews (CDSR), and
Cochrane Central Register of Controlled Trials (CCTR)
(up to November 2011). Both published and unpub-
lished trials were included, and no search restrictions
were imposed. Furthermore, the reference lists of all
selected studies were reviewed for further identification
of potential relevant articles.
Selection criteria
Inclusion criteria included all articles concerning patients
with gastric cancer who were allocated randomly to
receive surgery associated with intraperitoneal hyperther-
mic chemotherapy versus surgery without intraperitoneal
hyperthermic chemotherapy. The advanced gastric
cancer of the patients consisted of macroscopic serosal
invasion without distant metastases or peritoneal car-
cinomatosis. Studies were limited to human trials, and
there was no language restriction. If centers published
duplicate trials with an increased number of patients
or follow-up time period, we utilized the most com-
plete reports in the meta-analysis.
Date extraction and critical appraisal
Two reviewers (one clinical, Jingxu Sun, and one non-
clinical, Xiaowan Chen) reviewed each article independ-
ently, and discrepancies between the two reviewers were
resolved through discussion and consensus. The authors,
publication years, country of investigators, sample size,
total numbers for survival and death, the different
detailed chemotherapy regimens, follow-up period, cura-
tive effects, adverse events, surgery plans, and the peri-
toneal recurrence status of each trial were extracted
(Table 1). The quality of the trials was evaluated using
Jadad quality scores [13], and included secure methods
for randomization, allocation concealment, patient and
observer blinding, and loss to follow-up. The studies
were divided into a low quality group (score < 4) and
high quality group (score ≥ 4) (Table 2).
Statistical analysis
The end-point of the meta-analysis was overall survival,
defined as the time from treatment to the last follow-up
or death. Results regarding the overall survival in the
meta-analysis were reported as risk ratio (RR) with 95%
confidence interval (CI). The heterogeneity between
the trials and groups was studied using the χ2 test (or
Cochran Q statistic) for statistical significance, and
measured with I2 statistic for degree of heterogeneity
[14,15]. The I2 statistic is derived from the Q statistic
([Q-df/Q] × 100). I2 < 25 was considered to indicate low
heterogeneity and I2 >50% indicated a large degree of
heterogeneity. If there was major heterogeneity, a
random-effect model was used, and if there was no con-
spicuous heterogeneity, we chose a fixed-effect model
Table 1 Basic characteristics of trials included in the present study
Author Publication
years


























1 Koga S [16] 1988 Japan 8-10 μg/ml MMC, 8-12 L,
50-60 min, 44-45°C
4/26 7/21 30 26/26 21/21 NA NA
2 Hamazoe R [17] 1993 Japan 10 μg/ml MMC, 10-12 L,
50-60 min, 48-50°C
18/42 22/40 77 40/42 35/40 7* 13*
3 Fujimura T [18] 1994 Japan 30 mg MMC + 300 mg CDDP,
6-8 L,60 min, 41-42°C
7/22 14/18 36 NA NA 2* 4*
4 Ikeguchi M [19] 1995 Japan 8-10 μg/ml MMC, 8-10 L,
50-60 min, 44-45°C
38/78 52/96 60 78/78 96/96 27* 38*
5 Fujimoto S [20] 1998 Japan 10 μg/ml MMC, 3-4 L,
120 min, 44.5-45°C
27/71 36/70 96 67/71 65/70 1* 16*
6 Yonemura Y [21] 2001 Japan 30 mgMMC + 300 mg CDDP,
6-8 L, 60 min, 42-43°C
19/48 27/47 60 48/48 47/47 6 7
7 Zuo Y [22] 2004 China 80-100 mg CDDP + 1000 mg
5-FU + 5 mg, 2 L,60 min, 41–43°C
8/46 14/36 36 NA NA NA NA
8 Wei G [23] 2005 China 1000 μg/ml 5-UF, 4-5 L,
60 min, 43-45°C
21/42 25/46 36 40/49 49/55 NA NA
9 Zhang GY [24] 2007 China 30 mg MMC + 300 mg CDDP,
2 L, 30 min, 42-45°C
44/92 75/120 60 92/92 120/120 13 45
10 Deng HJ [25] 2009 China 300-500 μg/ml 5-FU,
3 L, 60-90 min, 42-43°C
18/44 27/41 60 44/44 41/41 NA NA

















Table 2 Quality assessment of trials included in the present study
Author Randomization Blind Allocation concealment Withdrawal and dropout Jadad Scroe
1 Koga S [16] without details no well reported well reported 4
2 Hamazoe R [17] without details no well reported well reported 4
3 Fujimura T [18] without details no without details well reported 3
4 Ikeguchi M [19] without details no unclear well reported 2
5 Fujimoto S [20] without details no unclear well reported 2
6 Yonemura Y [21] without details no without details well reported 3
7 Zuo Y [22] without details no unclear well reported 2
8 Wei G [23] well reported no well reported well reported 5
9 Zhang GY [24] well reported no well reported well reported 5
10 Deng HJ [25] well reported no well reported well reported 5
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significance was set at 0.05 for effect sizes. Publication
bias was tested using the funnel plot. All statistical ana-
lysis was performed by RevMan 5.1 software, which was
provided by Cochrane Collaboration.
Results
Eligible trials
We searched a total of 280 studies. Through screening
of the titles and reading the abstracts, 31 potentially
relevant reports were identified that included surgery
plus HIPC versus surgery alone. Of these 31 articles,
only ten randomized trials were fit the selection criteria
[16-25] and included in our study. The selection pro-
cedure was further summarized in Figure 1. The 1062Figure 1 Selection of included trials.gastric cancer patients enrolled in the studies were
divided into the HIPC group (n = 518) and control
group (n = 544), shown in Table 1. Of the ten trials, all
of the investigators were from Asia: six were from
Japan [16-21] and four were from China [22-25]. The
quality of the included trials was evaluated according
to the Jadad-scale (Table 2), and three trails [20,21,23]
were low quality according to the scores (< 4 scores).
Overall survival rates
The overall survival rate of the 1062 patients in the ten
studies was shown in Figure 2 [16-25] (518 in the HIPC
group and 544 in the control group). Seven trials used
MMC as the primary drug in HIPC [15-21] and three
used 5-FU.
Figure 2 Risk Ratios for overall survival rates of all 10 randomized controlled trials.
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group and 5-FU subgroup. As a result, significant survival
improvements were found in the HIPC group compared
to the control group, as well as in the MMC subgroup
(RR = 0.75, 95%CI 0.65-0.86; P < 0.00001; fixed-effect
model), and in the 5-FU group (RR = 0. 69, 95%CI 0.52-
0.90; P < 0.00001; fixed-effect model). There was no obvi-
ous statistical heterogeneity in the trials. All trials analysis
provided similar results (RR = 0. 73, 95%CI 0.64-0.83;
P < 0.00001; fixed-effect model) without statistical hetero-
geneity (I2 = 0%). Four trials [19,22,24,25] utilized systemic
chemotherapy after surgery for both the HIPC and controlFigure 3 Risk Ratios for overall survival rate of trials with or withoutgroups. We used additional analysis to obtain results that
were identical in the group without systemic chemo-
therapy (RR = 0.71, 95%CI 0.59-0.87; P < 0.00001; fixed-
effect model) and the group with systemic chemotherapy
(RR = 0.75, 95%CI 0.63-0.89; P < 0.00001; fixed-effect
model) (Figure 3). Sensitivity analysis was performed with-
out the low quality trials and the results were the same
(RR = 0.74, 95%CI 0.64-0.86; P < 0.00001).
Peritoneal dissemination
There were six studies [17-21,24] that reported recur-
rence in the abdominal cavity (Table 1). All of thesesystemic chemotherapy.
Sun et al. BMC Cancer 2012, 12:526 Page 6 of 10
http://www.biomedcentral.com/1471-2407/12/526six trials described the occurrence of peritoneal local-
regional recurrence, but four of them [17-20] only
supplied the number of patients who died from peri-
toneal recurrence. Hamazoe R [17], Fujimura T [18],
Ikeguchi M [19] and Fujimoto S [20] all supplied the
recurrence numbers of patients who died. In Hamazoe
R’s trial, 7 of 18 patients in the HIPC group died due to
peritoneum local-regional recurrence, and 13 of 22
patients died in the control group. In Fujimura T’s trial,
2 of 7 patients in the HIPC group died due to periton-
eum local-regional recurrence, and 4 of 14 patients died
in the control group. In Ikeguchi M’s trial, 27 of 38
patients in HIPC group died due to peritoneum local-
regional recurrence, and 38 of 52 patients died in the
control group. Also, in Fujimoto S’s trail, 1 of 27 patients
in the HIPC group died due to local recurrence, and 16
of 36 patients died in the control group. We explored
the relationships among these four trials, and attempted
to perform meta-analysis. However, we found that there
was significant heterogeneity (P = 0.02, I2 = 62%); thus,
we described the above four trials.
The remaining two trials reported the recurrence of all
patients, and we used these data for analysis. Figure 4
showed that HIPC exhibited a lower recurrence rate
compared to the control group (RR = 0.45, 95%CI 0.28-
0.72; P = 0.001; fixed-effect model), and the heterogen-
eity was not very significant between these trials. Thus,
HIPC may exhibit a significant preventive effect on
patients who received surgery for advanced gastric
cancer.
Adverse events
The adverse events included bone marrow suppression,
anastomotic leak, bowel fistula, adhesive ileus, and
liver disfunction. In our study, five trials [20,21,23-25]
reported bone marrow suppression: one patient in the
HIPC group and none in the control group in Yone-
mura Y’s trial, two patients in HIPC group and one in
the control group in Wei G’s group, and six patients
in HIPC group and four patients in the control group
in Deng HJ’s study; in the two remaining trials there
were no patients in either the HIPC group or control
group who exhibited bone marrow suppression. The
RR value was 1.68 (95%CI 0.62-4.58; P = 0.31; fixed-
effect model) and there were no statistically significantFigure 4 Risk Ratios for peritoneal dissemination.differences between the HIPC and control groups. Five
studies [16,17,20,21,24] reported anastomotic leak: in
Koga S’s group there was one patient in the HIPC
group and two patients in the control group, in Hama-
zoe R’s group there were two patients in the HIPC
group and three patients in the control group, and in
Ynoemura Y’s trial there was one patient in the HIPC
group and two patients in the control group. The RR
was 0.52 (95%CI 0.16-1.73; P = 0.29; fixed-effect model)
and had no statistical significance. Three trials
[20,21,24] reported the occurrence of bowel fistula:
there were two patients in each group of Fujimoto S’s
trial, one patient in the HIPC group and no patients in
the control group in Ynemura Y’s report. The RR was
1.38 (95%CI 0.28-6.85; P = 0.70; fixed-effect model) and
had no statistical significance. Three trials [16,17,22]
recorded adhesive ileus, in which Koga S reported one
patient in the HIPC group and two patients in the con-
trol group, Zuo Y described two patients in the HIPC
group and one patient in the control group. The RR
was 0.79 (95%CI 0.17-4.12; P = 0.77; fixed-effect model)
and there was no statistical significance. Similarly, five
studies reported the occurrence of liver dysfunction: in
Wei G’s trial there were two patients in each group,
there were three patients in the HIPC group and two
patients in the control group in both trials reported by
Zhang GY and Deng HJ, and the RR was 1.47 (95%CI
0.52-4.12; P = 0.47; fixed-effect model). In the other
trials, there were no reports regarding the adverse
events, or there were statistics of adverse events but no
patients specifically cited (Figure 5). The adverse event
results we obtained all exhibited no statistical signifi-
cance. Because of the different research aims of the
trials, the different adverse events were chosen. In the
future, more comprehensive evidence is warranted.
Discussion
The survival rate of patients with gastric cancer has
improved along with the improvement of surgical proce-
dures [26]. However, many patients who have received
gastric cancer resection still have suffered local-regional
or peritoneal recurrence. Dissemination of free tumor
cells through blood or lymph into the abdominal cavity
has been considered one of the most common causes of
peritoneal dissemination of gastric cancer [27]. Thus, it
Figure 5 Risk Ratios for adverse events.
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abdominal cavity in order to improve survival rates.
Intraperitoneal chemotherapy for intraperitoneal cancer
was first suggested in the 1950s [28]. Intraperitoneal
chemotherapy is able to kill the free tumor cells left be-
hind after surgery that were not eliminated by traditional
systemic chemotherapy. Hyperthermic intraperitoneal
chemotherapy was first performed as a clinical trial to
investigate removal of intraperitoneal tumor cells in
1980 [12]. HIPC washes out intraperitoneal free tumor
cells using a large massive liquid, and damages cancer
cells or micrometastases directly due to the heat sensi-
tivity of tumor cells [17,29]. Thus, HIPC combined with
surgery has been used to control peritoneal metastasis in
gastric cancer; however, there is still no solution as towhether it exhibits an effect on long-term survival and
prevention of peritoneal recurrence.
The purpose of a meta-analysis is to supply an ex-
haustive and neoteric summary of all relevant RCTs
concerning the topic, and to provide guidance for fu-
ture clinical work. Our present meta-analysis demon-
strated the effects of HIPC in correlation with different
chemotherapy regimens for patients who had received
advanced gastric cancer tumor resection in order to im-
prove the survival rate. In a study conducted by Xu DZ
et al. [10], intraperitoneal chemotherapy after cancer was
demonstrated to be beneficial to patients with gastric
cancer. Similar results were reported with six RCTs
on the topic by Yan TD et al. [8] in 2007, in which it
was demonstrated that hyperthermic intraoperative
Figure 6 Sensitivity analysis for overall survival: high-quality studies (Jadad score ≥ 4).
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early postoperative intraperitoneal chemotherapy (EPIC)
following resection of gastric cancer improved survival.
Sensitivity analyses (Figure 6) and funnel plot analyses
concerning potential publication bias (Figure 7) were also
performed to confirm the reliability of our research
results. The publication bias may be a problem for meta-
analysis, but we did not find this bias in our study.
In the past, many researchers have reported that ap-
proximately 50% of patients who received resection of
advanced gastric cancer exhibited a local-regional recur-
rence in their abdominal cavity and a poor prognosis
[30,31]. However, because few RCTs reported peritoneal
recurrence, the earlier studies could not be utilized to
analyze the relationship between the HIPC and control
groups regarding local-regional recurrence. We included
six trials that reported peritoneal local-regional recur-
rence, but only two trials supplied the recurrence rateFigure 7 Funnel plot analysis of potential publication bias.for all patients. The results of our meta-analysis indi-
cated that HIPC could potentially allow for a better
prognosis in patients who underwent resection for
advanced gastric cancer compared to the control group,
and may play a role in the prevention of peritoneal
local-regional recurrence. The other four trials, except
for the report by Ikeguchi M [19], all indicated that peri-
toneal recurrence was more frequent in the control
group compared to the HIPC group. Additionally, Ikegu-
chi M reported that HIPC potentially prevents periton-
eal metastases among patients with no lymph node
metastases. We also counted the type of radical surgery
received by the patients (Table 1), and a great majority
of patients received R0 resection. It was interesting that
patients of the two trails processed in meta-analysis were
all received R0 radical resection. Thus, for gastric cancer
patients (serosal invasion) with R0 resection but high
probability of peritoneal recurrence, HIPC may play an
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have reported total peritoneal recurrence is a problem
that we encountered; the study of a greater number of
interrelated studies is awaited.
The adverse events in the HIPC and control groups
were also described in our research. The independent
effects of hyperthermia for cancer cells is strongly in-
creased when the temperature range is 42.5°C to 43.0°C,
but because selective heating of only tumor cells is very
difficult the injury to normal tissues is also increased
[18]. In Yan TD’s [8] study, he reported that HIIC with
or without EPIC after resection of gastric cancer in-
creased the risk of intra-abdominal abscess and neutro-
penia. Few clinical trials have previously described the
side effects of HIPC, and in various reports differing
data were supplied. Our results indicated that there were
no statistically significant differences regarding adverse
events between the HIPC group and the control group.
However, further comprehensive proof is needed to con-
firm this.
Over the past couple of decades, several investigators
reported that HIPC significantly improved the survival
rate in serosa-invasive gastric cancer patients. This find-
ing was due to the prevention of early postoperative
peritoneal metastasis [26]. However, although our find-
ings indicated that the survival rate might be generally
significantly improved following HIPC, the individual
optimal regimen remains unclear, and further studies are
warranted. Also, the effectiveness of HIPC potentially
depends on the diameter and depth of the micrometas-
tasis, because heat or drugs cannot reach the cancer
cells [16,32,33]. However, there were several adverse
events after the treatment of HIPC that were not
avoided as common complications of chemotherapy. In
spite of the Jadad-scale was used to assess the investiga-
tions and all articles included in the studies were RCT,
the quality of RCT studies cannot be fully accessed. The
bias caused by quality of included articles may be a fac-
tor which may influence the result of the study. Al-
though the Jadad-scale is visualized and pellucid, a
consummate and exhaustive appraisal procedure is still
awaited. Additionally, all of the trials included in this
analysis were from Asia, particularly China and Japan.
Thus, whether HIPC is useful for other patients of the
world remains to be seen in further investigations.
Conclusion
In conclusion, our meta-analysis demonstrated that
HIPC potentially improves the overall survival rate of
patients who underwent resection for advanced gastric
cancer, and potentially functions by preventing local re-
currence. In the future, higher quality studies, superior
patient selection, and well designed multi-center RCTs
are awaited.Abbreviations
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